FIA
ABUS icon

FNY Investment Advisers’s Arbutus Biopharma ABUS Stock Holding History

FNY Investment Advisers’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,800
Closed -$11K – 665
2024
Q2 		$11K Buy
+3,800
New +$11.4K 0.01% 341
2020
Q3 		– Sell
-9,900
Closed -$18K – 462
2020
Q2 		$18K Hold
9,900
– – 0.01% 251
2020
Q1 		$9K Buy
+9,900
New +$26.8K 0.01% 300

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

FNY Investment Advisers's ABUS Position: Q3 2024 in Review

FNY Investment Advisers sold out of Arbutus Biopharma (ABUS) in Q3 2024, closing a stake of 3,800 shares — an estimated $11K sold.

FNY Investment Advisers first reported a position in ABUS in Q1 2020 and held it in 3 quarters. The position peaked at $18K in Q2 2020. 144 funds tracked by Wall St. Rank hold ABUS as of Q3 2024.

  • FNY Investment Advisers reported no remaining Arbutus Biopharma position as of Q3 2024 after selling out during the quarter.
  • FNY Investment Advisers sold 3,800 Arbutus Biopharma shares in Q3 2024, an estimated $11K.
  • FNY Investment Advisers first reported a position in Arbutus Biopharma in Q1 2020 and held it in 3 quarters.
  • FNY Investment Advisers's Arbutus Biopharma position peaked at $18K in Q2 2020.
  • 144 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2024.

Based on FNY Investment Advisers's 13F filing for Q3 2024, filed 18 Oct 2024.